XSHG
600216
Market cap1.65bUSD
Jul 10, Last price
11.83CNY
1D
1.89%
1Q
-25.92%
Jan 2017
-6.70%
Name
Zhejiang Medicine Co Ltd
Chart & Performance
P/E
13.03
P/S
1.28
EPS
0.91
Div Yield, %
3.19%
Shrs. gr., 5y
-0.14%
Rev. gr., 5y
3.92%
Revenues
8.88b
-5.28%
Net income
873m
-24.74%
CFO
1.89b
+54.15%
Dividend
Jul 21, 20250.37 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Medicine Co., Ltd. is a Chinese enterprise specializing in the manufacturing and distribution of both nutritional supplements and pharmaceutical goods. Its life nutrition portfolio encompasses a wide array of offerings, such as synthetic and natural vitamin E, vitamin A, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, and lycopene, alongside various other vitamin compounds. Beyond nutrition, the company is a significant supplier in the pharmaceutical sector. This includes the production of active pharmaceutical ingredients and raw materials like specialized antibiotics for drug-resistant strains, anti-malarial compounds, and quinolone derivatives. Furthermore, it develops and markets finished pharmaceutical products, notably sugar-based medications and hormonal preparations. Established in 1997, Zhejiang Medicine Co., Ltd. maintains its headquarters in Shaoxing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||